Boston Sci acquires two devices to treat CTOs
Boston Scientific has acquired a re-entry catheter and intraluminal chronic total occlusion (CTO) crossing device from S.I. Therapies and ReVascular Therapeutics that will help treat complex peripheral lesions.
The Natick, Mass.-based company said it acquired the re-entry catheter from Israel-based S.I. Therapies back in November 2010 and that the deal with Sunnyvale, Calif.-based ReVascular Therapeutics is expected to close this month. Additionally, Boston Scientific said that the products are expected to be launched globally in approved markets later this year.
While the financial details of the deals were not disclosed, Boston Scientific said that both transactions are expected to have an impact on adjusted earnings in 2011 and 2012 and be accretive thereafter.
The Natick, Mass.-based company said it acquired the re-entry catheter from Israel-based S.I. Therapies back in November 2010 and that the deal with Sunnyvale, Calif.-based ReVascular Therapeutics is expected to close this month. Additionally, Boston Scientific said that the products are expected to be launched globally in approved markets later this year.
While the financial details of the deals were not disclosed, Boston Scientific said that both transactions are expected to have an impact on adjusted earnings in 2011 and 2012 and be accretive thereafter.